公开(公告)号：US20240158368A1

公开(公告)日：2024-05-16

申请号：US18379351

申请日：2023-10-12

Applicant: AbbVie Inc.

Inventor： David A. Degoey ,  Michael R. Schrimpf ,  David J. Hardee ,  Jacob Ludwig ,  Eric R. Miller ,  Timothy R. Hodges ,  Alberto Munoz ,  Sarah J. Perlmutter ,  Huan-Qiu X. Li ,  Alvin Jang ,  Elizabeth L. Noey ,  Gregory A. Gfesser ,  Edgars Jecs ,  Robert G. Schmidt ,  Justin D. Dietrich ,  Xenia B. Searle ,  Boguslaw P. Nocek ,  Andrew Bogdan

IPC: C07D401/12 ,  A61P31/14

CPC classification number: C07D401/12 ,  A61P31/14

Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.

公开(公告)号：US20160120841A1

公开(公告)日：2016-05-05

申请号：US14925649

申请日：2015-10-28

Applicant: AbbVie Inc.

Inventor： Philip R. Kym ,  Xueqing Wang ,  Xenia B. Searle ,  Bo Liu ,  Ming C. Yeung ,  Robert J. Altenbach ,  Eric Voight ,  Andrew Bogdan ,  John R. Koenig

IPC: A61K31/353 ,  A61K45/06 ,  C07D405/14 ,  A61K31/4433 ,  C07D491/052 ,  A61K31/435 ,  A61K31/4025 ,  A61K31/453 ,  C07D413/14 ,  A61K31/5377 ,  A61K31/397 ,  C07D491/107 ,  C07D407/12 ,  A61K31/436

CPC classification number: C07D407/12 ,  A61K31/00 ,  A61K31/353 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/435 ,  A61K31/436 ,  A61K31/4433 ,  A61K31/453 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/14 ,  C07D413/14 ,  C07D491/052 ,  C07D491/107 ,  A61K2300/00

Abstract: The invention provides for compounds of formula (I) wherein R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中R1，X，Y，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，m和R“具有定义的任何值 在本说明书及其药学上可接受的盐中，其可用作治疗由CFTR介导和调节的疾病和病症的药剂，包括囊性纤维化，Siegren综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。 还提供了由一种或多种式（I）化合物组成的药物组合物。

公开(公告)号：US20160122331A1

公开(公告)日：2016-05-05

申请号：US14926727

申请日：2015-10-29

Applicant: AbbVie Inc.

Inventor： Philip R. Kym ,  Xueqing Wang ,  Xenia B. Searle ,  Bo Liu ,  Ming C. Yeung

IPC: C07D407/12 ,  A61K45/06 ,  A61K31/357

CPC classification number: C07D407/12 ,  A61K31/357 ,  A61K45/06

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and m are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐或放射性标记形式，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12和m如说明书中所定义，是有用的 在治疗由囊性纤维化跨膜电导调节剂（CFTR）蛋白质预防或改善的病症或障碍。 描述了制备化合物的方法。 还描述了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。